TNG462 is a MTA-cooperative PRMT5 inhibitor developed by Tango Therapeutics, under clinical investigation for MTAP-deleted cancers. It is a closely watched candidate in the PRMT5 research space.

CAS: { 2760483-96-1 }

Purity: ≥{98.1%}% (HPLC)

Stock: {576kg}

MOQ: {MOQ}（sample: 1 g）

Lead time: Samples: 3–5 days; Batch: 7–21 days

Documents: COA / HPLC / NMR / MSDS (available on request)

Physicochemical Properties

M.Wt	520.70
Formula	C28H36N6O2S
Appearance	Solid
Storage	Solide Powder -20°C 12 Months; 4°C 6 Months	In Solvent -80°C 6 Months; -20°C 6 Months
Solubility	10 mM in DMSO
Chemical Name/SMILES	N-(6-amino-5-ethylpyridin-3-yl)-2-[(2R,5S)-5-methyl-2-[2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-5-yl]piperidin-1-yl]-2-oxoacetamide

As a dedicated supplier of pharmaceutical intermediates and APIs, EOS Med CDMO offers for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.

Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.

Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.

Solubility: To be determined.

Shelf Life: Over 2 years under proper storage conditions.

Pharmaceutical Preparations: To be determined.

HS Code: 2934.99.9001

TNG462

TNG462 is a MTA-cooperative PRMT5 inhibitor developed by Tango Therapeutics, under clinical investigation for MTAP-deleted cancers. It is a closely watched candidate in the PRMT5 research space.

Physicochemical Properties

Talk with sales directly